Home / Spain / Oryzon Genomics, S.A.
Oryzon Genomics, S.A.
Short position disclosed on September 23, 2026.
Evolution of the disclosed total
April 1, 2025 today
Open positions
| Fund | Twelve months | % of capital | Over the year | Since |
|---|---|---|---|---|
| Voleon Capital Management LP | 0.59% | new | September 23, 2026 |
In the United States ORYZF (OTC): 30,045 shares sold short on August 31, 2026. FINRA names no fund.
On the other side: the funds that hold Oryzon Genomics, S.A. Titelia
Get the moves on Oryzon Genomics, S.A. by mail.
There is no account to create. You give an address, you confirm it through a link, and every message contains a link to stop.
History of disclosures
| Date | Fund | % of capital | End of publication |
|---|---|---|---|
| September 23, 2026 | Voleon Capital Management LP | 0.59% | still open |
| July 3, 2026 | Voleon Capital Management LP | 0.63% | |
| May 18, 2026 | Qube Research & Technologies Ltd | 0.00% | |
| April 28, 2026 | Qube Research & Technologies Ltd | 0.90% | |
| March 27, 2026 | Qube Research & Technologies Ltd | 0.80% | |
| March 11, 2026 | Qube Research & Technologies Ltd | 0.72% | |
| March 3, 2026 | Qube Research & Technologies Ltd | 0.63% | |
| March 2, 2026 | Qube Research & Technologies Ltd | 0.55% | |
| April 2, 2025 | Citadel Securities GCS (Ireland) Limited | 0.37% | |
| April 1, 2025 | Citadel Securities GCS (Ireland) Limited | 0.58% |
Download 10 filings as CSV Columns: Date, Fund, Market, Disclosed position, Unit, End date. The other formats
Other companies sold short in Spain
- Edreams Odigeo, S.A. 5.89% of the capital sold short
- Solaria Energia y Medioambiente, S.A. 5.61% of the capital sold short
- Enagas, S.A. 4.81% of the capital sold short
- Tecnicas Reunidas, S.A. 3.61% of the capital sold short
- Viscofan, S.A. 2.44% of the capital sold short
- Indra Sistemas, S.A. 2.17% of the capital sold short
- Grifols, S.A. 1.81% of the capital sold short
- Laboratorios Farmaceuticos Rovi, S.A. 1.51% of the capital sold short
- Ence Energia y Celulosa, S.A. 1.48% of the capital sold short
- Sacyr, S.A. 1.47% of the capital sold short
- Cellnex Telecom, S.A. 1.40% of the capital sold short
- Repsol, S.A. 1.24% of the capital sold short
Cite this page
The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.
QuiVad, Oryzon Genomics, S.A., source CNMV, data as at September 23, 2026, https://www.quivad.com/action/oryzon-genomics-s-a